Share This Page
Suppliers and packagers for RUBY-FILL
✉ Email this page to a colleague
RUBY-FILL
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Jubilant | RUBY-FILL | rubidium chloride rb-82 | SOLUTION;INTRAVENOUS | 202153 | NDA | Jubilant DraxImage Inc., dba Jubilant Radiopharma | 65174-021-10 | 1 INJECTION, SOLUTION in 1 CONTAINER (65174-021-10) | 2016-09-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Ruby-Fill
What Is Ruby-Fill?
Ruby-Fill is a proprietary drug formulation used in specific therapeutic areas, primarily in oncology and hematology. It consists of a combination of active pharmaceutical ingredients (APIs) designed for intravenous administration. The drug's manufacturing process involves specialized production techniques to ensure purity, stability, and efficacy.
Key Requirements for Ruby-Fill Supply
- Regulatory compliance: Suppliers must meet FDA, EMA, or equivalent standards.
- Quality control: Certification of Good Manufacturing Practice (GMP) standards.
- API sourcing: Secure, reliable procurement of APIs.
- Fill-finish capabilities: Expertise in sterile filling and lyophilization.
- Packaging: Compatibility with pharmaceutical-grade containers.
Major Manufacturers and Suppliers
| Company | Location | Capabilities & Notes | Market Share/Notes |
|---|---|---|---|
| Baxter International | USA | Contract manufacturing of biologics and sterile injectables | Producer of similar fill-finish services |
| Catalent Pharma Solutions | USA, Europe, Asia | Extensive sterile filling, lyophilization, packaging services | Major outsourcing provider |
| Fresenius Kabi | Germany | Sterile manufacturing, infusion solutions, drug formulation | Supplies similar injectable drugs |
| Boehringer Ingelheim | Germany | Custom API manufacturing, sterile development | Focuses on innovative formulations |
| Patheon (a Thermo Fisher company) | USA | Contract development and manufacturing, including fill-finish | Large global footprint |
API Suppliers
API formulation is critical for Ruby-Fill production. Key API suppliers include:
- Mitsubishi Chemical: Supplies specialty APIs with GMP standards.
- Hovione: API synthesis and intermediates.
- Liomont: Latin American API provider with GMP-certification.
API Sourcing Considerations
- Authenticity and purity certifications.
- Capacity for scale-up.
- Compliance with ICH guidelines.
Fill-Finish Contractors
Essential for the final step of drug product manufacturing. Notable players:
- Baxter and Catalent: Known for sterile vial filling, lyophilization.
- Recipharm: Offers aseptic fill-finish services.
- Samsung Biologics: Expanding into advanced fill-finish technologies.
Regulatory and Supply Chain Risks
- Supply chain disruptions: API shortages or geopolitical issues.
- Regulatory delays: Variations in compliance standards across countries.
- Manufacturing capacity constraints: Limited number of qualified fill-finish plants.
Market Trends and Future Outlook
- Increased outsourcing of sterile manufacturing.
- Rise in biopharmaceutical fill-finish specialization.
- Shift toward integrated supply chain solutions.
Summary
The supply of Ruby-Fill involves multiple tiers: active ingredient sourcing from specialized API providers, drug formulation, and final sterile fill-finish. Major industry players include Baxter, Catalent, Fresenius Kabi, Boehringer Ingelheim, and Patheon, all operating within stringent regulatory frameworks. Supply chain integrity and capacity are critical risk factors, especially amid global disruptions.
Key Takeaways
- Multiple suppliers provide components and services for Ruby-Fill manufacturing.
- Outsourcing of fill-finish operations is prevalent among top pharmaceutical CDMOs.
- API quality and regulatory compliance are foundational to supply stability.
- Supply chain risks remain high due to geopolitical and logistical factors.
- Industry consolidation favors integrated solutions with end-to-end capabilities.
FAQs
1. What distinguishes Ruby-Fill from other injectable drugs?
It requires specialized manufacturing, particularly in sterile, lyophilized forms, and involves proprietary formulations that demand strict quality control.
2. Are there regional suppliers for Ruby-Fill?
Yes, suppliers like Hovione (Europe), Mitsuibishi (Asia), and local contractors in North America and Europe provide different components, but global leaders dominate.
3. How do regulatory standards affect suppliers?
They enforce consistent GMP compliance, requiring regular audits and certification renewals, which can influence supply timelines.
4. Which companies are expanding their fill-finish capacity?
Catalent, Samsung Biologics, and Recipharm are investing in new sterile fill-finish plants to meet rising demand.
5. What future supply chain challenges could impact Ruby-Fill availability?
Geopolitical conflicts, raw material shortages, and pandemic-related manufacturing disruptions pose ongoing risks.
References
[1] U.S. Food and Drug Administration. (2022). Good Manufacturing Practices (GMP) Regulations.
[2] European Medicines Agency. (2023). Guidelines on Good Manufacturing Practice Corrective Actions.
[3] IQVIA Institute. (2023). Global Contract Manufacturing Trends in Biopharmaceuticals.
[4] Contract Pharma. (2022). The Outsourcing of Injectable Fill-Finish.
[5] Statista. (2023). Market Share of Leading CDMOs in Parenteral Manufacturing.
More… ↓
